US 12,090,209 B2
Twin base linkers for virus inactivation
Thomas J. Webster, Barrington, RI (US); and Mark A. Johanson, Concord, MA (US)
Assigned to Northeastern University, Boston, MA (US); and Audax Medical, Inc., Concord, MA (US)
Filed by Northeastern University, Boston, MA (US); and Audax Medical, Inc., Concord, MA (US)
Filed on Apr. 15, 2021, as Appl. No. 17/232,105.
Claims priority of provisional application 63/010,642, filed on Apr. 15, 2020.
Prior Publication US 2021/0322560 A1, Oct. 21, 2021
Int. Cl. A61K 47/65 (2017.01); A61K 31/155 (2006.01); A61K 31/519 (2006.01); A61K 47/64 (2017.01); A61P 31/14 (2006.01)
CPC A61K 47/65 (2017.08) [A61K 31/155 (2013.01); A61K 31/519 (2013.01); A61K 47/64 (2017.08); A61P 31/14 (2018.01)] 20 Claims
 
1. An antiviral composition comprising a plurality of functionalized twin base linker (TBL) molecules having the general structure

OG Complex Work Unit Chemistry
wherein the twin bases comprise a structure according to Formula 1

OG Complex Work Unit Chemistry
wherein L is the linker and comprises carbon, nitrogen, and/or oxygen atoms and has a chain length from about 4 to about 20 atoms;
wherein the peptide moiety serves as a backbone and contains from about 2 to about 20 L- and/or D-amino acids; and
wherein one or more targeting moieties are covalently linked to the peptide, and wherein each of the one or more targeting moieties consists of from 3 to 12 amino acids and is capable of specifically binding a surface-accessible protein of a virus, thereby deactivating the virus.